| Literature DB >> 34810225 |
Jean Lee1, Emily Cullum2, Kyle Stoltz3, Niklas Bachmann4, Zoe Strong5, Danielle D Millick6, Lisa K Denzin6,7, Anthony Chang5, Vera Tarakanova3, Alexander V Chervonsky8,5,9, Tatyana Golovkina8,4,9.
Abstract
H2-O (human HLA-DO) is a relatively conserved nonclassical MHC class II (MHCII)-like molecule. H2-O interaction with human HLA-DM edits the repertoire of peptides presented to TCRs by MHCII. It was long hypothesized that human HLA-DM inhibition by H2-O provides protection from autoimmunity by preventing binding of the high-affinity self-peptides to MHCII. The available evidence supporting this hypothesis, however, was inconclusive. A possibility still remained that the effect of H2-O deficiency on autoimmunity could be better revealed by using H2-O-deficient mice that were already genetically predisposed to autoimmunity. In this study, we generated and used autoimmunity-prone mouse models for systemic lupus erythematosus and organ-specific autoimmunity (type 1 diabetes and multiple sclerosis) to definitively test whether H2-O prevents autoimmune pathology. Whereas our data failed to support any significance of H2-O in protection from autoimmunity, we found that it was critical for controlling a γ-herpesvirus, MHV68. Thus, we propose that H2-O editing of the MHCII peptide repertoire may have evolved as a safeguard against specific highly prevalent viral pathogens.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34810225 PMCID: PMC9124240 DOI: 10.4049/jimmunol.2100650
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.426